IBRX: A Story — Why FDA Approval Is Only the Starting Line

01The framing: the movie does not end at approval

Picture the moment every biotech founder dreams of: the U.S. Food and Drug Administration has approved your drug. Champagne, a jump in the share price, headlines. For most people watching from the outside, that is where the movie ends — the underdog won, the medicine is real, roll credits.

It is the wrong place to end the movie. FDA approval is not the finish line. It is the starting gun. What happens after the approval — whether a permission-to-sell turns into a business that patients actually receive and shareholders actually get paid for — is a longer, harder, and far more interesting story than the approval itself. And almost nobody explains it in plain language.

So let us tell it as a story, using one company as our thread: ImmunityBio ($IBRX). Not as a recommendation — nothing here is advice — but because it is an unusually clean example. It has a product the FDA already approved. It has revenue that is rising. It has a billionaire founder who owns two thirds of the company and lends it money out of his own pocket. And it sits in a corner of medicine that suddenly got crowded. Three acts, three lessons that outlast this ticker: the human stakes, the commercial climb, and the question of who is really in charge.

02Act I — The stakes: keeping your organ

Every good story needs stakes you can feel in your gut. In this one, they are as human as it gets: whether a patient gets to keep their bladder.

ImmunityBio’s approved drug is called Anktiva. It treats an early form of bladder cancer that doctors call “non-muscle-invasive” — the tumor is still on the surface lining of the bladder and has not burrowed into the muscle wall. Caught here, it is one of the more treatable cancers. The problem is usually not death; the problem is that it keeps coming back, and each recurrence raises the pressure to do something drastic.

For decades the workhorse treatment at this stage has been something called BCG: the same old tuberculosis vaccine, repurposed as a bladder wash. A urologist drips it into the bladder through a catheter and provokes the immune system into attacking the cancer cells. It is cheap, it is old, and for many it works. But not for everyone, and not forever. When the tumor returns despite BCG, the patient earns a heavy label: “BCG-unresponsive.” That is the fork in the road that gives the whole story its meaning.

Historically, the recommended next step for a BCG-unresponsive patient was blunt and final: remove the bladder (radical cystectomy). It is a major operation. Surgeons build a new way for the body to pass urine, often using a piece of the intestine, and the patient lives with that reconstruction for the rest of their life. The cancer may be controlled, but the cost to daily life, body image, and dignity is enormous. This is the “enemy” the entire field is organized against.

This is exactly where Anktiva enters our story, as a concrete example. It is a lab-designed molecule (an “IL-15 superagonist,” if you want the technical name — think of it as a targeted amplifier for a specific arm of the immune system) given together with BCG. The idea is elegant: if BCG alone has stopped working, give the immune system a booster so the same standard therapy hits harder.

What the data showed — and why “durable” is the key word

The FDA approved Anktiva plus BCG in April 2024 for BCG-unresponsive patients with carcinoma in situ (a flat, aggressive form). The approval rested on a trial called QUILT-3.032. In the registrational population, about 62% of patients had a complete response — meaning that after treatment, doctors could find no remaining sign of the cancer. In a later analysis of a larger 100-patient cohort, the complete-response rate was reported as high as 71%.

But here is the part that separates a real advance from a headline. In cancer, getting a tumor to disappear once is not the whole game; keeping it gone is. On this, the follow-up data are the encouraging part: in the label population, with roughly 29 months of follow-up, there was about a 51% probability that a complete response would last at least 45 months, and among responders a large share stayed in response past one and two years. In the longer-term dataset covering flat and papillary disease, ImmunityBio reported that more than 80% of responders still had their bladder at 36 months, with disease-specific survival around 96% at three years in the papillary component.

Translated out of medical language, it says something simple and human: a meaningful number of patients responded, and — more importantly — the response tended to last, buying them years with their own bladder intact.

03Act II — The starting line: what happens after the FDA’s “yes”

Here is the misunderstanding at the heart of this whole article. Most people believe that once the FDA approves a drug, the company has “made it.” In reality, approval is just a license — a legal permission to sell. Turning that permission into a functioning business, with patients actually receiving the drug and cash actually coming in, is a separate, grinding, failure-prone job. Drug graveyards are full of approved products that never sold. This is exactly the stage $IBRX is living through now, in public — which is what makes it such a useful example.

Start with the scoreboard. ImmunityBio’s product revenue went from almost nothing in 2024 to roughly $113 million for full-year 2025 — a jump of more than 700%. The momentum carried into Q1 2026, with $44.2 million in a single quarter, about +168% year over year and +15% over the prior quarter’s $38.3 million. The company ended the quarter with about $381 million in cash and securities. These are not the numbers of a drug dying in a drawer: they are the fingerprints of a launch that is catching on.

But a number like “+700%” tells you that something is working without telling you what. The real lesson is understanding what a launch is made of — because a launch is not “the drug is good, so it sells itself.” It is a chain of separate stages, and it can jam at any single link:

1. Reimbursement and coverage — the invisible gatekeeper

Before a drug can sell at scale, someone has to agree to pay for it: insurers, health systems, hospitals. That means billing codes and coverage decisions. A therapy given in a doctor’s office, like Anktiva, has to slot into how clinics get reimbursed for in-office procedures. This stage is invisible in the headlines and decisive in reality: a brilliant drug with poor coverage sells poorly.

2. Physician adoption — changing what doctors do

Urologists have to know the drug exists, trust the data, and change their routine to use it. That requires a real commercial organization — sales reps, medical educators, conference presence — and it takes time. New medicine does not spread instantly; it spreads doctor by doctor, practice by practice.

3. Repeat use — the magic words “recurring revenue”

Here is a quiet advantage worth understanding. Anktiva is not a one-and-done pill; it is given in repeated cycles over time. From a business standpoint that creates recurring revenue — a patient who starts treatment keeps generating sales for as long as they stay on it. Markets love recurring revenue because it is more predictable and compounds as the patient base grows. It is the difference between selling someone an object and enrolling them in an ongoing relationship.

4. Geographic expansion — more countries, more market

A drug approved in only one country has one country’s worth of buyers. ImmunityBio has widened the map: Anktiva is now approved or authorized across roughly five regulatory jurisdictions covering some 34 countries, including the United States, the United Kingdom (MHRA), a positive opinion in the European Union, and Saudi Arabia (January 2026), backed by a Middle East commercial partnership. Each new geography is a new pool of patients — and a new reimbursement fight to win.

5. New indications — widening the label widens the pie

Perhaps the most powerful lever is widening who the drug is approved for. ImmunityBio has a supplemental application (sBLA) accepted by the FDA to extend Anktiva into BCG-unresponsive papillary disease without carcinoma in situ — a different, larger slice of the same population — with a decision set for January 6, 2027. It is also advancing a separate program in BCG-naïve patients (those getting BCG for the first time), where the pivotal trial is fully enrolled. Each label expansion, if it lands, does not just add patients: it moves the drug earlier and wider into the treatment journey.

04Act III — Who steers the ship

Every company has an ownership structure, and most of the time you can ignore it. Not here. ImmunityBio is not a widely held company where thousands of shareholders each own a sliver and management answers to a board of strangers. It is, in effect, one man’s company — and for anyone thinking about the stock, that single fact reshapes everything else.

The man is Patrick Soon-Shiong: a transplant surgeon who became one of the wealthiest people in American healthcare (he made his fortune developing the cancer drug Abraxane and building and selling pharmaceutical companies), the owner of the Los Angeles Times, and the founder, chairman, and chief scientific officer of ImmunityBio. Through a constellation of affiliated entities — Nant Capital, Cambridge Equities, California Capital Equity, NantWorks — he controls roughly 66% of the company. Two thirds. In practice, on any shareholder vote, he decides.

For a small investor, that concentration is a double-edged sword, and it is worth holding both edges at once.

The safety net

A founder who owns two thirds of his company is not going to walk away from it. Soon-Shiong is deeply aligned: this is his life’s work and the bulk of his public net worth. He has repeatedly done something most outside shareholders cannot: funded the company himself, through loans structured as notes convertible into shares. When a small biotech is burning cash to fund a launch, having a billionaire owner who will backstop it is a real form of insurance. He is unlikely to let his creation die for lack of money.

The catch

That same control is also the risk. When one person holds the majority, minority shareholders are passengers, not co-pilots — they are along for whatever ride the founder chooses. And the way he keeps the company funded has a cost that lands on those holders: dilution. Every time new shares are issued — to raise money, to convert those insider loans, to pay employees — the pie is sliced into more pieces, and each existing slice gets thinner. Over the past year, ImmunityBio’s share count grew by nearly 19%, past one billion. Revenue can rise while your personal claim on it shrinks. Both can be true at once, and usually are.

05The nuance that makes you think

A story that only flatters its subject is marketing, not analysis. The reason IBRX is genuinely interesting — not just a nice chart — is that it contains real tension. There are two “yes, buts,” and they are the most instructive part of the whole piece.

Hold the two paradoxes together and you have the honest version of the bull case and the bear case in the same frame: a real, growing, approved product in a high-need setting (the bull), tethered to a scarce ingredient and surrounded by well-funded competition (the bear). That tension is the story. Anyone who tells you it is all one way is selling you something.

06The tool: how to read the next newly approved biotech

This is the part you keep. Forget the specific figures above; what is worth carrying forward is a small, reusable checklist to point at any biotech with a freshly approved drug. Next time a headline crosses your screen — “Company X’s drug approved,” “Company X reports record quarter,” “FDA accepts expanded filing” — run it through four questions:

1. Which rung is the news about? Is it the already-approved use, or an expansion into a bigger market — new disease, earlier stage, new country? Expansion widens the pie; a mere reiteration of the existing use does not.
2. Is the launch curve accelerating? Is revenue rising quarter over quarter, not just year over year? Is the product used repeatedly (recurring revenue) or only once?
3. Is there coverage, and a market? Are insurers actually paying? Is it reaching new geographies? An approval without reimbursement is a trophy on a shelf, not a business.
4. Who pays the bills? How much cash is there versus how fast it burns? Who controls the company — and are they diluting you while funding growth?

Try it on this very story. A headline like “ImmunityBio’s papillary filing accepted, decision set for January 2027” scores on question one (it is an expansion to a bigger slice of patients) — but a disciplined reader immediately files it under question four too, because expansion usually has to be paid for. That is the whole trick: the questions do not give you an answer, they give you a way to interrogate the news, so you are never at the mercy of a headline again.

07The map of the neighbors

To keep your bearings, here is who shares Anktiva’s room — early-stage bladder cancer that no longer responds to BCG. This is context, not a set of recommendations; these are the names you will see recur, and knowing where each sits makes every future headline easier to place.

Notice the pattern: the field splits by modality — systemic drug, gene therapy, immune booster, slow-release device, cheap generic — and along a single practical axis: does it need BCG or not? That axis alone will explain a surprising share of the news to come.

08Risks: what still has to be proven

• Competition is arriving in force. With J&J’s device, CG Oncology’s virus, and cheap generic chemo aiming at the same patients, market share is contested, not guaranteed. A fast start does not lock in the finish.
• The BCG dependency is a structural vulnerability. Tying the product to a chronically scarce ingredient exposes it to supply shocks and hands rivals a talking point.
• Reimbursement and commercial execution have to keep compounding. The revenue ramp is notable, but launches can slow if coverage talks stall or adoption plateaus. The next several quarters matter more than the last one.
• Founder control and dilution cut both ways. The majority owner is a backstop and a governance concentration at once; insider financing and share issuance dilute minority holders and should be tracked as an ongoing variable, not a one-time footnote.
• The label expansion is not yet in hand. The papillary indication is a binary regulatory event with a January 6, 2027 decision — a potential catalyst, not a settled fact.
• Profitability is still a story about the future. Rapid revenue growth is not sustained profit; the burn, the cash runway, and the path to self-funding remain the numbers to watch.

09Bottom line

“IBRX: A Story” turns out not to be a story about a bladder drug at all. It is a story about the three forces that decide whether any FDA approval becomes a durable company: how much a patient’s benefit truly lasts, how many unglamorous stages separate the regulator’s “yes” from real revenue, and who is holding the wheel while it all plays out. ImmunityBio is an unusually rich example because it puts all three on the table at once and in public — an approved product whose sales are climbing steeply, a field filling up with well-funded rivals, and a founder who owns two thirds of the game and lends it his own money.

The thing to carry away is not a verdict on this one stock. It is a way of seeing. The next time you meet a “just approved” biotech, you will be able to take it apart yourself, calmly, in three moves: what is really at stake for the patient, whether the launch curve is bending the right way, and who pays the bills. That is a skill. And a skill, unlike a stock tip, keeps working long after the headline that taught it has scrolled away.